Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on Ma...( - Data demonstrates safety and effi...),Health

- Data demonstrates safety and efficacy of first FDA-approved nebulized

formoterol fumarate in patients with moderate to severe COPD -

NAPA, Calif., May 16 /PRNewswire/ -- Dey, L.P. announced today that three clinical data presentations will be given at the International Conference of the American Thoracic Society (ATS) on May 20, 2008 at the Metro Toronto Convention Center. One of the presentations details the effects on dyspnea and other COPD symptoms of using Perforomist(TM) Inhalation Solution, nebulized formoterol fumarate, adjunctively with tiotropium to treat COPD patients. The other two presentations compare the clinical effect of two types of drug delivery - nebulization versus DPI - when treating COPD patients with formoterol fumarate.

Perforomist(TM) (formoterol fumarate) Inhalation Solution was approved in 2007 by the FDA for long-term, twice-daily maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is the only FDA- approved nebulized formoterol fumarate.

For those attending ATS, the three presentations are available as follows:

-- "Addition of Nebulized Formoterol Fumarate to Tiotropium Treatment

Relieves Dyspnea and Symptoms in COPD Patients," Poster Board #F4

-- "Dose-Ranging Study in COPD Patients Comparing Pharmacodynamics of

Formoterol Fumarate Delivered by Nebulization and DPI," Poster Board

#F13

-- "A Pharmacokinetic Study in COPD Patients Comparing Formoterol Fumarate

Delivered by Nebulization and DPI," Poster Board #F14

Poster Viewing: Tuesday May 20th, 10:45 AM - 12:15 PM EDT

Room: Area F (Halls A-B, North Building, Level 300), Metro Toronto

Convention Centre

Session Info: Thematic Poster Session, [C42] COPD Pharmacotherapy I:

Effects of Bronchodilators

Please note that the principal investigators will be
'/>"/>